Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2899-2907

  Lukowsky, Lilia R ^a,b   Molnar, Miklos Z ^a,c   Zaritsky, Joshua J ^d   Sim, John J ^e   Mucsi, Istvan ^c,f   Kovesdy, Csaba P ^g,h   Kalantar Zadeh, Kamyar ^a,b,d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

Author keywords

hemodialysis; mineral and bone disorders; mortality; parathyroid hormone; polycystic kidney disease

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE DISEASE; BONE MINERAL; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEMODIALYSIS; HUMAN; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MINERAL DEFICIENCY; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DISEASES, METABOLIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MINERALS; POLYCYSTIC KIDNEY DISEASES; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84864401488     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr747     Document Type: Article

References (50)

1. United States Renal Data System. Excerpts from USRDS 2009 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2010; 55: Suppl 1 S1.
2. Shoji T, Maekawa K, Emoto M et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis 2010; 210: 145-149.
3. Raggi P, Giachelli C, Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007; 4: 26-33.
4. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127.
5. US Renal Data SystemUSRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the Untied States 2009; Vol. 3 Betheda, MDNational Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease.
6. Abbott KC, Agodoa LY. Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival. BMC Nephrol 2002; 3: 7.
7. Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. Ann Intern Med 1984; 101: 238-247.
8. Milutinovic J, Fialkow PJ, Agodoa LY et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med 1984; 53: 511-522.
9. Rizk D, Jurkovitz C, Veledar E et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 2009; 4: 560-566.
10. Alam A, Perrone RD. Management of ESRD in patients with autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 164-172.
11. Fourtounas C, Panteris V, Valis D. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2002; 39: 660.
12. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784.
13. Pirson Y, Christophe JL, Goffin E. Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1996; 11Suppl 6 24-28.
14. Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease-the patient on renal replacement therapy. Nephrol Dial Transplant 1996; 11Suppl 6 18-20.
15. Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002; 57: 208-214.
16. Orskov B, Romming Sorensen V, Feldt-Rasmussen B et al. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010; 5: 2034-2039.
17. Pavik I, Jaeger P, Kistler AD et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 2011; 79: 234-240.
18. Molnar MZ, Streja E, Kovesdy CP et al. High platelet count as a link between renal cachexia and cardiovascular mortality in endstage renal disease patients. Am J Clin Nutr 2011; 94: 945-954.
19. Kalantar-Zadeh K, Miller JE, Kovesdy CP et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 2010; 25: 2448-2458.
20. Kalantar-Zadeh K, Streja E, Kovesdy CP et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85: 991-1001.
21. Kalantar-Zadeh K, Cano NJ, Budde K et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol 2011; 7: 369-384.
22. Miller JE, Kovesdy CP, Nissenson AR et al. Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 2010; 55: 100-112.
23. Miller JE, Kovesdy CP, Norris KC et al. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 2010; 32: 403-413.
24. Molnar MZ, Lukowsky LR, Streja E et al. Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens 2010; 28: 2475-2484.
25. Streja E, Kovesdy CP, Molnar MZ et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893.
26. Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000; 11: 520-529.
27. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932.
28. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
29. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793.
30. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
31. Dukkipati R, Kovesdy CP, Colman S et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr 2010; 20: 243-254.
32. Ni Z, Smogorzewski M, Massry SG. Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 1994; 135: 1837-1844.
33. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1024-1029.
34. Carlstedt E, Ridefelt P, Lind L et al. Interleukin-6 induced suppression of bovine parathyroid hormone secretion. Biosci Rep 1999; 19: 35-42.
35. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
36. Nielsen PK, Rasmussen AK, Butters R et al. Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun 1997; 238: 880-885.
37. Shantouf RS, Budoff MJ, Ahmadi N et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol 2010; 31: 419-425.
38. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
39. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
40. Kovesdy CP, Kuchmak O, Lu JL et al. Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 468-476.
41. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203.
42. Hill AB. The environment and disease: association or causation?. Proc R Soc Med 1965; 58: 295-300.
43. Kalantar-Zadeh K. What is so bad about reverse epidemiology anyway?. Semin Dial 2007; 20: 593-601.
44. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355-1363.
45. Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 2007; 3: 134-144.
46. Hruska KA, Saab G, Mathew S et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-315.
47. Martola L, Barany P, Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of china?. Blood Purif 2005; 23: 203-210.
48. Heemskerk S, Masereeuw R, Moesker O et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37: 417-423 e411.
49. Schwedler SB, Coresh J, Schinzel R. Advanced glycation end products and mortality in caring for ESRD. Kidney Int 2000; 11: 520-529.
50. Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303.